{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:53:58Z","timestamp":1789588438837,"version":"build-2803163510"},"reference-count":21,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However, clinical activity of venetoclax and TKI-based regimens is unknown. Methods: We conducted a retrospective study on patients with Ph+ AML (n = 7) and CML-MBP (n = 9) who received venetoclax combined with TKI-based regimens at our institution. Results: Median patient age was 42 years, and the median number of prior therapy cycles was 5 (range 2\u20138). Nine patients received decitabine-based, and 7 received intensive chemotherapy-based regimens. Ten patients (63%) received ponatinib. The overall response rate (ORR) in 15 evaluable patients was 60% (1 complete remission [CR], 6 CR with incomplete hematologic recovery [CRi], 1 morphologic leukemia-free state, and 1 partial response). The ORR was 43% in Ph+ AML and 75% in CML-MBP. The median overall survival (OS) for all patients was 3.6 months, for AML OS was 2.0 months, and for CML-MBP OS was 10.9 months. The median relapse-free survival for AML and CML-MBP was 3.6 and 3.9 months, respectively. Compared to nonresponders, patients achieving CR\/CRi had higher baseline Ph+ metaphases and BCR-ABL1 PCR. Conclusions: Combination therapy of venetoclax with TKI-based regimens shows encouraging activity in very heavily pretreated, advanced Ph+ leukemias, particularly CML-MBP.<\/jats:p>","DOI":"10.1159\/000506346","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T21:00:35Z","timestamp":1586898035000},"page":"567-573","source":"Crossref","is-referenced-by-count":74,"title":["Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias"],"prefix":"10.1159","volume":"143","author":[{"given":"Abhishek","family":"Maiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel\u00a0J.","family":"Franquiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge\u00a0E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias\u00a0J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval\u00a0G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan\u00a0M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina\u00a0Y.","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney\u00a0D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop\u00a0M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas\u00a0J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31041-9"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30864"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22233"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1309\/B4NVER1AJJ84CTUU"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.027"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.10.008"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0249-2"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0609"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0364"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.6.977"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.12.011"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27568"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5428.5428"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800026"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.07.004"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.08.101"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf5309"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/aha\/article-pdf\/143\/6\/567\/3897669\/000506346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/aha\/article-pdf\/143\/6\/567\/3897669\/000506346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:49:43Z","timestamp":1745423383000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000506346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,12,1]]},"published-print":{"date-parts":[[2021,2,9]]}},"URL":"https:\/\/doi.org\/10.1159\/000506346","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}